IP Library Granted Patent US 7,005,141
Granted Patent B2
US 7,005,141 · App. 10/225,104 · Granted Feb 28, 2006

Oral drug delivery compositions and methods

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,005,141
App. No.
10/225,104
Granted
Feb 28, 2006
Kind
B2
Abstract

The present invention relates to an oral drug delivery system, and in particular to modified amino acids and modified amino acid derivatives for use as a delivery system of sensitive agents such as bioactive peptides. The modified amino acids and derivatives can form non-covalent mixtures with active biological agents and in an alternate embodiment can releasably carry active agents. Modified amino acids can also form drug containing microspheres. These mixtures are suitable for oral administration of biologically active agents to animals. Methods for the preparation of such amino acids are also disclosed.

Claims (77)

1. A composition comprising:

(A) at least one biologically-active agent; and

(B) a compound having the formula:

Ar—Y—(R 1 ) n —OH

wherein:

Ar is a substituted or unsubstituted phenyl;

Y is

R 1 has the formula

wherein:

R 3 is C 1 to C 24 alkyl;

R 4 is hydrogen, C 1 to C 4 alkyl, or C 1 to C 4 alkenyl; and

n is equal to 1.

2. The composition of claim 1 , wherein said biologically-active agent is selected from the group consisting of a peptide, a polysaccharide, a mucopolysaccharide, a carbohydrate, a lipid or any combination thereof.

3. The composition of claim 2 , wherein said biologically-active agent is a peptide.

4. The composition of claim 2 , wherein said biologically-active agent is a polysaccharide.

5. The composition of claim 2 , wherein said biologically-active agent is a mucopolysaccharide.

6. The composition of claim 1 , wherein said biologically-active agent is selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-I, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, or any combination thereof.

7. The composition of claim 6 , wherein said biologically-active agent is human growth hormone.

8. The composition of claim 6 , wherein said biologically-active agent is interferon.

9. The composition of claim 6 , wherein said biologically-active agent is insulin.

10. The composition of claim 6 , wherein said biologically-active agent is heparin.

11. The composition of claim 6 , wherein said biologically-active agent is low molecular weight heparin.

12. The composition of claim 6 , wherein said biologically-active agent is calcitonin.

13. The composition of claim 6 , wherein said biologically-active agent is erythropoietin.

14. The composition of claim 6 , wherein said biologically-active agent is an antigen.

15. The composition of claim 6 , wherein said biologically-active agent is cromolyn sodium.

16. A dosage unit form comprising

(A) the composition of claim 1 ; and

(B) (a) an excipient

(b) a diluent,

(c) a disintegrant,

(d) a lubricant,

(e) a plasticizer,

(f) a colorant,

(g) a dosing vehicle, or

(h) any combination thereof.

17. The dosage unit form of claim 16 , comprising a tablet, a capsule, or a liquid.

18. The dosage unit form of claim 17 , wherein said biologically-active agent is selected from the group consisting of a peptide, a polysaccharide, a mucopolysaccharide, a carbohydrate, a lipid or any combination thereof.

19. The dosage unit form of claim 18 , wherein said biologically-active agent is a peptide.

20. The dosage unit form of claim 18 , wherein said biologically-active agent is a polysaccharide.

21. The dosage unit form of claim 18 , wherein said biologically-active agent is a mucopolysaccharide.

22. The dosage unit form of claim 17 , wherein said biologically-active agent is selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-I, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, or any combination thereof.

23. The dosage unit form of claim 22 , wherein said biologically-active agent is human growth hormone.

24. The dosage unit form of claim 22 , wherein said biologically-active agent is interferon.

25. The dosage unit form of claim 22 , wherein said biologically-active agent is insulin.

26. The dosage unit form of claim 22 , wherein said biologically-active agent is heparin.

27. The dosage unit form of claim 22 , wherein said biologically-active agent is low molecular weight heparin.

28. The dosage unit form of claim 22 , wherein said biologically-active agent is calcitonin.

29. The dosage unit form of claim 22 , wherein said biologically-active agent is erythropoietin.

30. The dosage unit form of claim 22 , wherein said biologically-active agent is an antigen.

31. The dosage unit form of claim 22 , wherein said biologically-active agent is cromolyn sodium.

32. A method for preparing a composition, said method comprising mixing:

(A) at least one biologically-active agent; and

(B) a compound having the formula:

Ar—Y—(R 1 ) n —OH

wherein:

Ar is a substituted or unsubstituted phenyl;

Y is

R 1 has the formula

wherein:

R 3 is C 1 to C 24 alkyl, (C 1 to C 10 alkyl) phenyl, or phenyl (C 1 to C 10 alkyl);

R 4 is hydrogen, C 1 to C 4 alkyl, or C 1 to C 4 alkenyl; and

n is equal to 1.

33. The method of claim 32 , wherein said biologically-active agent is selected from the group consisting of a peptide, a polysaccharide, a mucopolysaccharide, a carbohydrate, a lipid or any combination thereof.

34. The method of claim 33 , wherein said biologically-active agent is a peptide.

35. The method of claim 33 , wherein said biologically-active agent is a polysaccharide.

36. The method of claim 33 , wherein said biologically-active agent is a mucopolysaccharide.

37. The method of claim 32 , wherein said biologically-active agent is selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-I, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, or any combination thereof.

38. The method of claim 37 , wherein said biologically-active agent is human growth hormone.

39. The method of claim 37 , wherein said biologically-active agent is interferon.

40. The method of claim 37 , wherein said biologically-active agent is insulin.

41. The method of claim 37 , wherein said biologically-active agent is heparin.

42. The method of claim 37 , wherein said biologically-active agent is low molecular weight heparin.

43. The method of claim 37 , wherein said biologically-active agent is calcitonin.

44. The method of claim 37 , wherein said biologically-active agent is erythropoietin.

45. The method of claim 37 , wherein said biologically-active agent is an antigen.

46. The method of claim 37 , wherein said biologically-active agent is cromolyn sodium.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2021
From: EMISPHERE TECHNOLOGIES, INC.
To: NOVO NORDISK NORTH AMERICA OPERATIONS A/S
Reel/Frame 056750/0169 →
SECURITY AGREEMENT Recorded Oct 3, 2005
From: EMISPHERE TECHNOLOGIES, INC.
To: MHR INSTITUTIONAL PARTNERS IIA LP
Reel/Frame 016617/0145 →